Labcorp (LH)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-30
$361.39-1.84%
Close 2026-10-30 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-10-30
Research Workspace
Put LH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
The reason to own it still holds.
View ThesisRevenue growth is slowing — up about 6% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 20%.
View QualityManagement screens strong on earnings delivery.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskLH’s case rests on strong recent financial performance and steady revenue growth. Its latest quarter’s revenue growth accelerated, though the increase was modest. Revenue grew 6.9% year over year in Q3 2026, and adjusted EPS beat consensus. LH trades at 20× P/E versus a 22× peer median, despite its 16.8× historical multiple. The price reflects less growth than our forecast, though the premium to its own history remains a valuation risk. A 21% next-quarter miss probability and the data breach challenge the case. Peer multiples imply a price about 14% below where it trades; our read remains intact. This read is provisional.
Trailing returns as of 2026-10-30. LH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 19 analysts currently covering LH (as of Oct 2026).
Based on 8 Wall Street analysts offering 12-month price targets for LH in the last 4 months.
Continue this research
Compare LH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| LH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-10-30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Services — fair value, gap to price, and forward P/E.
Compare the value case
Put LH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
2026 EPS guidance and estimated PAMA headwind inform the outlook but do not materially alter the intact thesis.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-30. EPS is implied from price ÷ P/E. Not investment advice.
Current $361.39
The last 12 months of price, then the range of analyst 12-month targets from today’s $361.39.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Data breach raises concerns about security and operational integrity.
Advances: Expand Specialty Testing and Oncology Offerings
Acquisition enhances specialty testing and oncology capabilities.
Advances: Expand Specialty Testing and Oncology Offerings
New Alzheimer's test expands specialty testing offerings.
Advances: Increase 2026 Adjusted EPS Guidance
Partnership enhances growth potential in oncology.
Advances: Update 2026 Revenue Guidance
AI app launch supports revenue growth initiatives.